Pfizer's Prevnar 13 Backed by U.S. Panel for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:10PM CDT
Pfizer's (PFE) Prevnar 13 has been backed for regular use in patients aged 65 years and above.
Merck's Insomnia Drug Belsomra Approved by the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:00PM CDT
Merck (MRK) announced that the FDA has approved Belsomra.
Global Contraceptives Market 2014-2018: Key Vendors are Actavis, Bayer, Johnson & Johnson's, Janssen, Merck & Co, Pfizer and Teva
PR Newswire Europe - Thu Aug 14, 1:36PM CDT
DUBLIN, Aug. 14, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/5kt24m/global] has announced the addition of the "Global Contraceptives Market 2014-2018" [http://www.researchandmarkets.com/research/5kt24m/global] report to their offering.
DrugDev Continues to Collaborate, Share Ideas and Innovate With Clinical Trial Leaders and Global Investigators at Key Upcoming Conferences This Fall
Business Wire - Thu Aug 14, 12:06PM CDT
DrugDev is committed to collaborating and sharing ideas with sponsors, CROs and sites to understand their challenges and to develop innovative technology-driven solutions that enable them to do more trials together. DrugDev executives and technologists will speak and participate at key industry conferences in September and October, including...
GTCR Announces Partnership With David Snow to Form Cedar Gate Technologies
Business Wire - Thu Aug 14, 10:27AM CDT
GTCR, a leading private equity firm, today announced that it has entered into a partnership with David Snow to form Cedar Gate Technologies, LLC ("Cedar Gate"
Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
PR Newswire - Thu Aug 14, 8:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and actress S. Epatha Merkerson are bringing the America's Diabetes Challenge: Get to Your Goals program to Dallas, Texas to encourage African Americans with type 2 diabetes to know their A1C--their average blood sugar level over the past two to three months--and talk to their doctors about setting and attaining a personal A1C goal. Merkerson, one of the 4.9 million African-American adults living with type 2 diabetes, will attend the American Diabetes Association's Live Empowered event in Dallas, Texas at Concord Church on August 14 to share her story.
Why Pfizer (PFE) Stock Is Up Today
at The Street - Thu Aug 14, 7:25AM CDT
The company won the backing of a key U.S. advisory panel to recommend its vaccine Prevnar 13 for people ages 65 and older to help prevent infections including pneumonia.
Global Sun Care Product Market 2014-2018: Key Vendors are Beiersdorf, Johnson & Johnson, L'Oreal and Merck
GlobeNewswire - Thu Aug 14, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p3rf75/global_sun_care) has announced the addition of the "Global Sun Care Product Market 2014-2018" report to their offering.
Must-See Charts: 5 Big Stocks to Trade for Gains
at The Street - Thu Aug 14, 6:00AM CDT
Here's how to trade some of the biggest stocks on Wall Street.
Merck wins US FDA's approval for BELSOMRA for the treatment of insomnia in adults
M2 - Thu Aug 14, 4:41AM CDT
Healthcare company Merck (NYSE:MRK) reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for BELSOMRA (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep.
Growth Factors (Blood and Tissue) Market 2014 - Global Strategic Business Report
M2 - Thu Aug 14, 2:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqzzts/growth_factors) has announced the addition of the "Growth Factors (Blood and Tissue) - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins) - Tissue Growth Factors. The report profiles 90 companies including many key and niche players such as: - Alseres Pharmaceuticals, Inc. - Amgen, Inc. - Bayer HealthCare Pharmaceuticals, Inc. - Biogen Idec Inc - BioMimetic Therapeutics, Inc. - Biopharm GmbH - Bolder Biotechnology, Inc. - F. Hoffmann-La Roche Ltd - Chugai Pharmaceutical Co. Ltd. - Genentech, Inc. - FibroGen, Inc. - Johnson & Johnson - Janssen Biotech, Inc. - Lonza Group - Merck Serono International S.A. - NsGene A/S - PeproTech, Inc. - Reliance GeneMedix Plc - Sangamo BioSciences, Inc. - Sanofi - Shantha Biotechnics - Scil Proteins GmbH - Wockhardt Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Market Overview 2. Growth Factors An Overview 3. Research Studies & Clinical Trials 4. Product Innovations/Introductions 5. Recent Industry Activity 6. Focus On Select Players 7. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 90 (including Divisions/Subsidiaries 95) - The United States (42) - Japan (
Merck Statement regarding Role of PNEUMOVAX(R) 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults
Business Wire - Wed Aug 13, 4:58PM CDT
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices' (ACIP's) updated pneumococcal vaccine recommendations for adults 65 years of age and older. These recommendations call for a two vaccine regimen utilizing a dose of the pneumococcal conjugate vaccine followed by a dose of Merck's PNEUMOVAX(R) 23, at an interval to be determined by the ACIP, in adults 65 years of age and older who have not previously received pneumococcal vaccine. ACIP also voted that these recommendations for routine use of the pneumococcal conjugate vaccine in adults 65 years of age and older should be reevaluated in 2018 and revised as needed. ACIP will continue to monitor disease trends and the impact of these new recommendations.
FDA Approves BELSOMRA(R) (suvorexant) for the Treatment of Insomnia
Business Wire - Wed Aug 13, 3:49PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA(R) (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep. BELSOMRA (pronounced bell-SOM-rah) is a highly selective antagonist for orexin receptors. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. The mechanism by which BELSOMRA exerts its therapeutic effect is presumed to be through antagonism of orexin receptors. In the clinical trials to support efficacy, BELSOMRA was superior to placebo for sleep latency and sleep maintenance as assessed both objectively by polysomnography and subjectively by patient-estimated sleep latency. The recommended dose of BELSOMRA is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. The total dose should not exceed 20 mg once daily.
Look for Shares of Merck to Potentially Pullback after Yesterday's 1.44% Rise
Comtex SmarTrend(R) - Wed Aug 13, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.16 to a high of $57.89. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.14 on volume of 10.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Merck to Potentially Pullback After Gaining 1.44% Yesterday
Comtex SmarTrend(R) - Wed Aug 13, 3:43PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.16 to a high of $57.89. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $57.14 on volume of 10.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FDA approves new sleeping drug from Merck
By MATTHEW PERRONE - AP - Wed Aug 13, 3:39PM CDT
WASHINGTON (AP) — Merck & Co. Inc. has won federal approval for a new type of sleeping pill designed to help people with insomnia stay asleep.
Dow Today: Merck (MRK) Higher
at The Street - Wed Aug 13, 1:00PM CDT
The Dow component leading the way higher looks to be Merck (NYSE:MRK), which is sporting a 70-cent gain (+1.2%) bringing the stock to $57.73.
Western Blotting (Instruments (Manual/Semi-automated/Automated) Market - Global Forecast to 2018
M2 - Wed Aug 13, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6nsxqt/western_blotting) has announced the addition of the "Western Blotting Market by Product, Consumables, by Application - End-User Analysis & Global Forecast to 2018" report to their offering. Western blotting is one of the most commonly used confirmatory tests for diagnosing diseases. This technique is extensively used in many pharmaceutical and biotechnology industries, academic research institutes, and diagnostic laboratories. This technique comprises a number of manual error-prone steps, hence companies are launching automated instruments. Thus, the instruments are increasingly being adopted by researchers as they not only simplify the work and give accurate results but also save considerable time. Automation in the western blotting workstations, global increase in life science R&D spending, growing proteomics market, rising prevalence of HIV, and companies focusing on validating the antibodies are the key factors that are expected to drive the growth of this market. However, high costs of primary antibodies and the emergence of alternative technologies restrain the growth of this market. The global western blotting market is categorized into four broad segments, namely, products, applications, end users, and geographies. On the basis of products, the market comprises instruments and consumables. Instruments are further sub-segmented by type into manual, semi-automated, and automated. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Western Blotting Market, By Product 5 Global Western Blotting Market, By Application 6 Global Western Blotting Market, By End User 7 Global Western Blotting Market, By Geography 8 Competitive Landscape 9 Company Profiles Companies Mentioned: - Advansta Inc. - Assay Horizons, Inc. - Bio-Rad Laboratories, Inc. - GE Healthcare - Li-Cor Biosciences - Merck Millipore - Perkinelmer, Inc. - Proteinsimple, Inc. - Roche Applied Science - Sigma-Aldrich Corporation - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/6n...n_blotting